Last reviewed · How we verify
NCT03690453
Effect of Ivermectin Metabolites on Mosquito Survival
Phase 4 trial testing Ivermectin in Healthy in 20 participants. Completed in 5 April 2022.
5 April 2022
Quick facts
| Lead sponsor | University of Oxford |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 20 |
| Start date | 4 February 2019 |
| Primary completion | 5 April 2022 |
| Estimated completion | 5 April 2022 |
| Sites | 1 location across Thailand |
Drugs / interventions tested
- Ivermectin (ivermectin) — full drug profile →
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
University of Oxford
Who can join
Adults 18 to 60, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial will be designed to capture the full duration of mosquito-lethal effect of single dose Ivermectin to aid efforts to characterize metabolites with mosquito-lethal effect. Ivermectin and its metabolites likely have antiparasitic properties against asexual and sexual stage Plasmodium parasites that will be investigated with plasma samples from this study. This is an open-label pharmacokinetic study. Ten healthy participants will be admitted in the inpatient ward to receive a single oral dose of IVM (400 µg/kg). Another 10 healthy participants will be donate blood up to 42 ml each times for up to 3 times. There is no drug administration for these participants. The total duration for each volunteer's participation in the study is approximately 2 months.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Identification of the metabolites of ivermectin in humans.
Tipthara P, Kobylinski KC, Godejohann M, Hanboonkunupakarn B, et al · · 2021 · cited 34× · PMID 33497030 · DOI 10.1002/prp2.712 -
Author Correction: Ivermectin metabolites reduce Anopheles survival.
Kobylinski KC, Tipthara P, Wamaket N, Chainarin S, et al · · 2024 · cited 1× · PMID 39448768 · DOI 10.1038/s41598-024-76902-z -
A dynamic pharmacometric framework defining the relationship between ivermectin exposure and mosquito lethality
Hoglund RM, Kobylinski KC, Jittamala P, Hanboonkunupakarn B, et al · · 2026 · DOI 10.21203/rs.3.rs-8338994/v1
Verify or expand the search:
- PubMed search for NCT03690453
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ivermectin
Trials testing the same drug.
- NCT07396714 — the Efficacy of Ivermectin Alone or With Microneedling in Treatment of Cutaneous Warts. · EARLY_PHASE1 · not yet recruiting
- NCT07145736 — Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical · Phase 4 · recruiting
- NCT05605925 — Ivermectin-artemisinin Combination Therapy for Eradication of Malaria · Phase 4 · unknown
- NCT05045937 — Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19 · unknown
- NCT05643820 — Comparison of Oral Ivermectin and Permethrin 5% Lotion in Treatment of Pediculosis Capitis · Phase 1 · completed
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other University of Oxford trials
Trials by the same sponsor.
- NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) · Phase 2 · not yet recruiting
- NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults · Phase 1 · not yet recruiting
- NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis · not yet recruiting
- NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE · Phase 3 · not yet recruiting
- NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03690453 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Oxford
- Last refreshed: 26 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03690453.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing